BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34915638)

  • 41. Breast cancer brain metastases - A 12 year review of treatment outcomes.
    De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
    Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of locoregional recurrence and distant metastasis in Japanese breast cancer patients using Japanese standard postoperative radiation fields: Experience at a single institution.
    Takuwa H; Tsuji W; Yotsumoto F; Yamauchi C
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1191. PubMed ID: 32721113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
    Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
    JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer.
    Chi Y; Yao L; Hu X; Huang S; Huang N; Li S; Shao Z; Wu J
    Oncotarget; 2016 Mar; 7(12):14951-62. PubMed ID: 26908452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
    Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
    Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
    Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.
    Cossetti RJ; Tyldesley SK; Speers CH; Zheng Y; Gelmon KA
    J Clin Oncol; 2015 Jan; 33(1):65-73. PubMed ID: 25422485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.
    Azim HA; Kroman N; Paesmans M; Gelber S; Rotmensz N; Ameye L; De Mattos-Arruda L; Pistilli B; Pinto A; Jensen MB; Cordoba O; de Azambuja E; Goldhirsch A; Piccart MJ; Peccatori FA
    J Clin Oncol; 2013 Jan; 31(1):73-9. PubMed ID: 23169515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prognostic analysis of benign, borderline and malignant phyllodes tumors of the breast].
    Wang H; Wang X; Wang C
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):923-7. PubMed ID: 26887622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
    Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
    Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer.
    Karatas F; Sahin S; Erdem GU; Ates O; Babacan T; Akin S; Sever AR; Ozisik Y; Altundag K
    J BUON; 2016; 21(4):851-858. PubMed ID: 27685905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases.
    Genin AS; De Rycke Y; Stevens D; Donnadieu A; Langer A; Rouzier R; Lerebours F
    Breast; 2016 Dec; 30():222-227. PubMed ID: 26456897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
    Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
    Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
    Hanrahan EO; Broglio KR; Buzdar AU; Theriault RL; Valero V; Cristofanilli M; Yin G; Kau SW; Hortobagyi GN; Rivera E
    Cancer; 2005 Sep; 104(6):1158-71. PubMed ID: 16047352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.